Moderna CEO says Covid vaccines will evolve like ‘an iPhone’

Moderna CEO says Covid vaccines will evolve like 'an iPhone'
Written by admin

like covid-19 keep mutatingModerna will need to keep upgrading the vaccines that made it a global household name as it tries to make it more convenient for consumers, CEO Stéphane Bancel said in an interview with CNN Business on Wednesday.

He estimated a timeline of “three to five years” for the new combo product and compared the development of the life-saving jab to that of a smartphone.

“You don’t get the amazing camera, amazing everything when you first get an iPhone, but you do get a lot of stuff,” he said.

“A lot of us buy a new iPhone every September, and you get new apps and you get updated apps. And that’s the exact same idea, which is you’re going to get Covid, flu and RSV.” [respiratory syncytial virus] in your pod.”
Health Care Stocks May Keep Your Portfolio From Needing a Checkup
Having recorded dizzying growth during the pandemic, modern (mRNA) now it is under pressure to identify its next great frontier.

Bancel believes the Covid-19 pandemic that has helped the company rack up tens of billions of dollars in revenue and generate business in more than 70 markets globally could be over as soon as this year.

That doesn’t mean the virus is going anywhere, he noted.

“I think we are moving slowly, if not already in some countries, towards a world where all the tools are available and everyone can make their own decisions based on their tolerance for risk,” he explained, adding that he believed more people would choose to “live with the virus”, as they do with the flu.

The approach, however, will continue to vary widely, such as among immunocompromised people or in countries like Japan, where wearing masks was common even before the pandemic, he acknowledged.

And “there is always a 20% chance that we will get a very nasty variant that causes a very serious disease that has a lot of mutations,” he added.

the next big thing

Still, Moderna is determined not to become a one-hit wonder.

The company has more than 40 products in development and is planning for life well beyond Covid-19, Bancel said.

In addition to an updated annual booster, it continues to develop a personalized cancer vaccine, for which new clinical data will be released later this year. Bancel said the product could be approved in about two years if all goes well.

The company is also exploring a potential monkeypox vaccine, which “is still in the lab today,” Bancel said. World Health Organization declared the global outbreak of the disease a Public Health Emergency of International Concern last month.

And Moderna is looking to catch up with competitors abroad.

Earlier this year, it announced a push across 10 Asian and European markets, including Singapore, Hong Kong, Denmark and the Netherlands. The investments will cost “dozens of millions of dollars” and will include hundreds of new hires, Bancel said.

Members of the public waiting in line at a vaccination center administering the Moderna Covid-19 vaccine in Taipei, Taiwan, in April.  The company is reaching further into Asia this year by creating new subsidiaries.
He sees that as just a wave of expansion that will eventually see Moderna stop operating directly in 12 countries this year to “40 to 60 countries” over the next three years.
The company also recently signed manufacturing agreements in the United Kingdom, South Korea and Australia, and hopes to establish one or two more plants in Southeast Asia or North Asia.

Bancel said the new facility would be crucial in helping to tailor its products to the different strains of disease developing around the world.

Pfizer and Moderna created vaccines that save lives.  So why are its stocks falling apart?

When the world first faced the onset of Covid-19, Moderna was one of the few big manufacturers to rush to prepare its vaccines, cutting lead times from years to months. Its shares are up 434% in 2020 and 143% last year.

But now, as partners Pfizer (PFE) Y BioNTech (BNTX)the company’s shares have collapsedfalling more than 30% so far this year and 64% from its all-time high a year ago.
Last week, the company disclosed that it made a writedown of nearly $500 million in the second quarter, in part due to a sudden cancellation of orders from Covax, the international vaccination program for low-income countries.

The reversal caused huge losses for the company, which had bought new machines to fill those orders and, more importantly, caused Covid vaccines to be thrown away, Bancel said.

“We ended up destroying vaccines,” he said. “It was really heartbreaking.”

The CEO said he was not concerned that such a drop in demand would be repeated in richer countries, in part because governments had already shown commitments to use vaccines by the end of this year to prevent the reintroduction of economic lockdowns.

But “on the low-income country side, yes, I am concerned,” he said.

About the author


Leave a Comment